Why the study?
Cardiac pathology is a frequent comorbidity in COVID-19 patients, and associated cardiac arrhythmias may be aggravated by proarrhythmogenic drugs used to treat the infection.
Highlights the risk of proarrhythmogenic drug interactions when treating COVID-19 in patients with underlying cardiovascular diseases.
Answers are grounded in this paper and cite their sources.
Warrants arrhythmia vigilance with COVID-19 therapies in cardiac patients; leaves open prospective validation of proarrhythmogenic risks.
The article discusses the issues of drug interactions in the treatment of COVID-19 patients with concomitant cardiovascular diseases. It was revealed, that the most frequent comorbid background in patients with COVID-19 is cardiac pathology. Cardiac arrhythmias are observed in many cases, which can be aggravated by the proarrhythmogenic effect of drugs used to treat the novel coronavirus disease.
No takes yet. Share an insight, caveat, or question.
Арамисова et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: